Somatically acquired, activating mutations of GNAS, the gene encoding the stimulatory G-protein Gsa subunit, have been identified in kidney, thyroid, pituitary, leydig cell, adrenocortical and, more recently, in colorectal tumours, suggesting that mutations such as R201C may be oncogenic in these tissues. To study the role of GNAS in intestinal tumourigenesis, we placed GNAS R201C under the control of the A33-antigen promoter (Gpa33), which is almost exclusively expressed in the intestines. The GNAS R201C mutation has been shown to result in the constitutive activation of Gsa and adenylate cyclase and to lead to the autonomous synthesis of cyclic adenosine monophosphate (cAMP). Gpa33 tm1(GnasR201C)Wtsi/ þ mice showed significantly elevated cAMP levels and a compensatory upregulation of cAMP-specific phosphodiesterases in the intestinal epithelium. GNAS R201C alone was not sufficient to induce tumourigenesis by 12 months, but there was a significant increase in adenoma formation when Gpa33 tm1(GnasR201C)Wtsi/ þ mice were bred onto an Apc Min/ þ background. GNAS R201C expression was associated with elevated expression of Wnt and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase (ERK1/2 MAPK) pathway target genes, increased phosphorylation of ERK1/2 MAPK and increased immunostaining for the proliferation marker Ki67. Furthermore, the effects of GNAS R201C on the Wnt pathway were additive to the inactivation of Apc. Our data strongly suggest that activating mutations of GNAS cooperate with inactivation of APC and are likely to contribute to colorectal tumourigenesis.
Introduction
Genome-wide exon re-sequencing studies of human cancers have identified a number of frequently mutated genes that are associated with cancer formation and progression; however, their functional significance is unknown (Sjoblom et al., 2006; Wood et al., 2007) . One potentially interesting candidate is GNAS, the gene encoding the stimulatory G-protein alpha subunit (Gsa), which is situated on human chromosome 20q13.3. Heterotrimeric G-proteins that are composed of a-, band g-subunits mediate signal transduction from a large number of hormone and growth factoractivated seven-transmembrane receptors to diverse intracellular signalling pathways (Weinstein et al., 2004) . Ligand-bound G-protein-coupled receptors activate the Gs-protein by promoting the exchange of guanosine diphosphate for guanosine triphosphate on Gsa, which results in dissociation from the receptor and the bg-complex. The free Gsa subunit interacts with adenylate cyclase to stimulate the synthesis of cyclic adenosine monophosphate (cAMP) until hydrolysis of guanosine triphosphate returns it to the inactive guanosine diphosphate-bound form, which reassociates with the bg-complex to enter a new cycle (Weinstein et al., 2004) .
Somatically acquired, activating mutations of GNAS have been identified in adrenal hyperplasia, ovarian cysts, thyroid carcinomas (5%), adrenocortical, pituitary (22-40%), kidney (17%) and leydig cell tumours (67%) (Landis et al., 1989; Fragoso et al., 1998; Hayward et al., 2001; Kalfa et al., 2006; Palos-Paz et al., 2008; Taboada et al., 2009 ). Furthermore, several reports have documented the presence of thyroid, pituitary and adrenocortical tumours in patients with McCune-Albright syndrome, a mosaic disease caused by sporadic, post-zygotic, activating mutations of GNAS (Happle, 1986; Kirk et al., 1999; Yang et al., 1999; Collins et al., 2003; Fragoso et al., 2003; Chen et al., 2004; Weinstein et al., 2004) . The common mutations of GNAS that have been identified in tumours, including R201C, R201H and Q227R, are thought to inhibit guanosine triphosphate hydrolysis and result in the constitutive activation of Gsa and its effector adenylate cyclase, leading to autonomous synthesis of cAMP (Landis et al., 1989) . Collectively, these data suggest that activating mutations of GNAS can modify cell growth and may be oncogenic; however, how GNAS functions as an oncogene remains unclear.
Interestingly, a number of studies have reported an association between McCune-Albright syndrome and multiple gastrointestinal polyps (MacMahon, 1971; Weinstein et al., 1991) . More recently GNAS R201C mutations were identified in 9% of colorectal tumours (3/35; Sjoblom et al., 2006; Wood et al., 2007) . The most frequent early event in 480% of sporadic colorectal carcinomas is loss-of-function mutations of the adenomatous polyposis coli (APC) gene, which is also mutated in the germline of patients with familial adenomatous polyposis (Nishisho et al., 1991) . APC forms a complex with axin and glycogen synthase kinase 3b, which results in the phosphorylation of b-catenin and consequently its degradation through the ubiquitinproteasome system (Castellone et al., 2005) . Apc Min/ þ mice represent a valuable model of intestinal tumourigenesis, as sporadic loss of heterozygosity of the wild-type allele of Apc recapitulates the initiation of adenomagenesis observed in humans (Levy et al., 1994) . A number of groups have shown that loss of cyclooxygenase-1 or -2 (COX) dramatically reduces tumour formation in Apc Min/ þ mice (reviewed in Taketo, 2006) . Accordingly, the expression of PTGS1 and 2 (COX-1 and 2, respectively) has been shown to be upregulated in approximately 80% of colorectal adenomas and carcinomas and COX inhibition represents a valuable therapeutic target (Eberhart et al., 1994) . COX-1 and -2 synthesize the pro-inflammatory metabolite prostaglandin E2, which activates prostaglandin receptors 2 and 4 (EP2 and EP4), resulting in the activation of Gsa, adenylate cyclase and cAMP synthesis. The effects of COX-2 on intestinal tumour formation have been shown to be mediated by EP2 receptor activation (Castellone et al., 2005) , suggesting that both the spatial and temporal production of cAMP is important in intestinal tumourigenesis. The promotion of intestinal tumourigenesis by COX-2 is thought to be due to the direct binding of activated Gsa to the regulator of G-protein signalling domain of axin, which promotes the release of glycogen synthase kinase 3b from the complex and its inactivation. Furthermore, on the loss of APC, the threshold of Wnt pathway activation by constitutively active Gsa is thought to be lowered (Castellone et al., 2005) . Therefore, loss of APC or activation of Gsa is predicted to lead to reduced degradation and increased nuclear translocation of b-catenin. Constitutively active b-catenin/T-cell factor/ lymphocyte enhancer factor (TCF-LEF)-mediated transcription leads to the expression of growth-promoting genes and the transformation of normal crypts into the earliest colorectal cancer precursor lesions, called dysplastic aberrant crypt foci or monocryptal/oligocryptal adenomas (reviewed in Radtke and Clevers, 2005) .
Activating mutations of either KRAS or BRAF are found in 40-50% of colorectal cancers (Bos, 1989; Brink et al., 2003) and lead to activation of the extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase (ERK1/2 MAPK) pathway, which enhances proliferation, neoplastic transformation, differentiation and survival of many cell types (Barbacid, 1987) . cAMP has been shown to have opposing effects on cell growth: cAMP either inhibits or stimulates ERK1/2 MAPK-mediated cell proliferation and/or differentiation in a cell-type-specific manner (reviewed in Stork and Schmitt, 2002) . Whether elevated levels of cAMP result in the activation of the ERK1/2 MAPK pathway and growth of intestinal cells is not known.
Here, we have generated mice that specifically express GNAS R201C in the intestinal stem cells and all epithelial cell lineages from E14.5 into adulthood Johnstone et al., 2000) to assess whether this mutation participates in the formation and/or progression of colorectal cancer in vivo.
Results
Generation of an intestine-specific conditional Gpa33 tm1(GnasR201C)Wtsi allele Full-length human GNAS complementary DNA was synthesized to introduce the putative oncogenic mutation R201C. The mutation R201C was chosen over R201H and Q227R because it is found more frequently in cancers; however, both mutations have been shown to have a similar affect on adenylyl cyclase stimulation (Landis et al., 1989) . To express the mutant GNAS R201C cDNA specifically in the intestinal epithelium, we obtained and modified a Lox-Stop-Lox targeting vector to place it under the control of the endogenous Gpa33-antigen gene promoter ( Figure 1a ; Orner et al., 2002) . This approach was used to avoid complications that may arise from imprinting at the endogenous Gnas locus and extra-intestinal phenotypes such as those observed in patients with McCune-Albright syndrome (Plagge et al., 2008) . Upon Cre-mediated recombination of the loxP sites, GNAS R201C cDNA is predicted to be expressed bicistronically from the Gpa33 gene locus ( Figure 1a ). In adult mice Gpa33 is exclusively expressed throughout the epithelium of the intestinal tract, thus directing mutant GNAS R201C expression exclusively to proliferating and differentiating intestinal epithelial cells and crypt stem cells . The linearized conditional Gpa33 tm1(GnasR201C)Wtsi vector was electroporated into Bruce4 C57BL/6J mouse embryonic stem cells and correctly targeted clones were identified by Southern blot analysis ( Figure 1b ) and polymerase chain reaction. The F1 conditional Gpa33 tm1(GnasR201C)Wtsi/ þ males generated were crossed with CMV-Cre À/À females. A total of 69 progeny were obtained from 10 litters: 34 were Gpa33 tm1(GnasR201C)Wtsi/ þ , 35 were Gpa33 þ / þ , and all were heterozygous for CMV-Cre. This is the expected 1:1 Mendelian ratio; therefore, expression of mutant GNAS R201C from the Gpa33 locus does not cause embryonic lethality.
Expression of GNAS R201C from the Gpa33 locus RT-PCR expression analysis was performed on RNA, extracted from a range of tissues from Gpa33 tm1(GnasR201C)Wtsi/ þ and wild-type (Gpa33 þ / þ ) littermates using primers specific for the Gpa33 locus (exon 5) and the mutant GNAS cDNA. As expected, a 1.1 kb product was only generated from the intestinal tissue of Gpa33 tm1(GnasR201C)Wtsi/ þ mice ( Figure 1c ). The transcript was not present in other nonintestinal tissues of Gpa33 tm1(GnasR201C)Wtsi/ þ mice or in the intestinal tissue of wild-type littermate controls. Cloning and sequencing of the product generated from the intestines of Gpa33 tm1(GnasR201C)Wtsi/ þ mice revealed that the expected spliced transcript contained Gpa33 exons 5, 6 and 7 followed by LoxP-IRES-GNAS R201C cDNA sequences.
Enhanced cAMP levels and upregulation of cAMP-specific phosphodiesterases in the intestinal epithelium of Gpa33 tm1(GnasR201C)Wtsi/ þ mice The GNAS R201C mutation is thought to constitutively activate Gsa and adenylate cyclase and to lead to autonomous production of cAMP (Landis et al., 1989) . We used immunofluorescence and flow cytometry to show that expression of GNAS R201C leads to a 1.5fold increase in cAMP levels in the intestinal epithelium of Gpa33 tm1(GnasR201C)Wtsi/ þ mice relative to wild-type littermate controls (Po0.05; Figure 1d ). In the long term, high levels of cAMP are subjected to negative feedback control by upregulation of phosphodiesterases (Conti and Beavo, 2007) . We therefore determined the expression of the cAMP-specific phosphodiesterases 4a, 4b, 7a, 8a and 8b by real-time reverse transcriptase-PCR. Expression of Pde4a and Pde8b was upregulated by 2.5-fold in the intestinal epithelium of Gpa33 tm1(GnasR201C)Wtsi/ þ mice relative to control mice (P ¼ 0.05), whereas expression levels of Pde4b and Pde8a were unchanged ( Figure 1e ). Expression of Pde7a was negligible in this tissue.
Gpa33 tm1(GnasR201C)Wtsi/ þ mice do not develop intestinal polyps by 12 months of age To establish the phenotypic effect of expression of mutant GNAS R201C in the intestine, we aged a cohort of 21 Gpa33 tm1(GnasR201C)Wtsi/ þ and 20 wild-type littermate control mice to 12 months. Macroscopic and histological analysis did not reveal any polyp formation in the intestines, suggesting that by itself the activating GNAS R201C mutation is not sufficient to generate intestinal neoplasms (Figure 2a ).
The GNAS R201C mutation promotes intestinal adenoma formation in Apc Min/ þ mice To further explore the role of the GNAS R201C mutation in intestinal adenoma formation, we crossed Gpa33 tm1(GnasR201C)Wtsi/ þ mice with Apc Min/ þ mice. Mice were killed at 16 weeks to determine the number, size and location of intestinal adenomas in the small and large intestines. The mean number of adenomas in Apc Min/ þ mice (C57BL6) was 30±2.9 (mean±s.e., n ¼ 12), which is comparable to data obtained in other studies (Figure 2a ; Su et al., 1992) . The activating R201C mutation of GNAS resulted in a mean adenoma number of 62 ± 5.2 (n ¼ 11), a twofold increase (P ¼ 0.0001; Figures 2a and b ). The majority of intestinal adenomas were in the small intestine and showed a distribution very similar to that of Apc Min mice ( Supplementary Figure 1) . There was no difference in the dysplastic grade of adenoma between the two cohorts of mice-all were low-grade, non-invasive, tubular or tubulovillous adenomas typical of Apc Min mice (Figures 2b and c) . Collectively these data show that activation of GNAS cooperates with inactivation of Apc in the formation of intestinal adenomas.
Activation of Wnt and ERK1/2 MAPK pathways and enhanced proliferation in the intestines of Gpa33 tm1(GnasR201C)Wtsi/ þ mice To identify a mechanism for the enhanced formation of adenomas in Apc Min/ þ mice carrying the mutant GNAS R201C allele, we examined two of the most important signalling pathways in intestinal tumourigenesis, the ERK1/2 MAPK and Wnt pathways. cAMP signalling has been shown to activate ERK1/2 MAPKs in a cell-type-specific manner (Stork and Schmitt, 2002; McCubrey et al., 2007) . Immunohistochemical analysis of the small intestines revealed a significant increase in the number of nuclei that stained positively for phosphorylated-ERK1/2 MAPK within the crypt region (P ¼ 0.0453; Figure 3a ) of Gpa33 tm1(GnasR201C)Wtsi/ þ relative to wild-type littermate control mice. In agreement with this, western blot analysis showed a twofold increase in the amount of phosphorylated-ERK1/2 MAPK relative to total ERK1/2 MAPK (P ¼ 0.05; Figure 3b ). Phosphorylated-ERK1/2 MAPK activates transcription factors such as c-Myc and consequently leads to enhanced expression of the transcription factor c-Fos (McCubrey et al., 2007) . Expression of Fos was increased twofold in Gpa33 tm1(GnasR201C)Wtsi/ þ mice relative to wild-type littermate control mice (P ¼ 0.02; Figure 3c ).
Gsa has been implicated in the aberrant activation of Wnt signalling by COX2 and prostaglandin E2 (Castellone et al., 2005) ; therefore, we examined the expression of two Wnt target genes, Myc and Birc5 (survivin), by real-time reverse transcriptase-PCR (Giles et al., 2003) . Both Myc and Birc5 were upregulated twofold, suggesting significant activation of the Wnt pathway in Gpa33 tm1(GnasR201C)Wtsi/ þ intestines when compared with control mice (P ¼ 0.05; Figure 3c ). To test whether the effects of loss of Apc and activation of Gnas on the Wnt pathway were additive, we determined the expression of Myc and Birc5 in intestinal polyps. Myc was upregulated 1.5-fold and Birc5 was upregulated 2-fold in intestinal polyps from Apc Min/ þ Gpa33 tm1(GnasR201C)Wtsi/ þ mice compared with polyps from Apc Min/ þ mice (Po0.05 for both; Supplementary  Figure 2 ). Pgts2 (COX-2) expression has been reported to be upregulated by both the Wnt and ERK1/2 MAPK pathways (Araki et al., 2003) ; however, we found no evidence to suggest that Pgts2 is upregulated in Gpa33 tm1(GnasR201C)Wtsi/ þ intestines (Figure 3c) , indicating that the effects of GNAS R201C occur independently and downstream of COX-2.
c-Myc and c-Fos transcription factors coordinate the expression of genes that drive cellular proliferation and/or differentiation. There was a significant increase in the number of nuclei that stained positively for Ki67 within the crypt region of Gpa33 tm1(GnasR201C)Wtsi/ þ mice relative to Gpa33 þ / þ (P ¼ 0.005; Figure 3a ), suggesting that activation of GNAS R201C within the intestine augments proliferation. Immunohistochemical and histological analysis of the differentiated cells of the intestinal tissue revealed no difference in the number of enteroendocrine (P ¼ 0.1282), Paneth (P ¼ 0.8102), goblet (P ¼ 0.1735), mitotic cells (P ¼ 0.1735) and apoptotic fragments (P ¼ 1.0; Supplementary Figure 3 ), suggesting that the activating R201C mutation of GNAS has no effect on the differentiation or apoptosis of intestinal cells.
Discussion
Somatically acquired, activating mutations of GNAS have been identified in kidney, thyroid, leydig cell, pituitary and adrenocortical tumours (Landis et al., 1989; Fragoso et al., 1998; Hayward et al., 2001 However, a recent mutational analysis of 35 colorectal cancers by Sjoblom et al. (Sjoblom et al., 2006; Wood et al., 2007) was the first study to suggest that the R201 mutations of GNAS occur frequently (9%) in colorectal cancers. Furthermore, a number of studies have reported an association between McCune-Albright syndrome, a mosaic disease caused by sporadic, postzygotic, activating mutations of GNAS, and multiple gastrointestinal polyps (MacMahon, 1971; Weinstein et al., 1991) . However, how GNAS functions in this context remains unclear.
To examine the role of GNAS R201C in intestinal tumourigenesis, we generated mice expressing GNAS R201C under the control of the Gpa33-antigen promoter, which is almost exclusively expressed by intestinal stem cells and all epithelial cell lineages from E14.5 into adulthood Johnstone et al., 2000) . Gpa33 tm1(GnasR201C)Wtsi/ þ mice were shown to express mutant GNAS R201C in the intestine, which led to a significant increase in cAMP levels in the intestinal mucosa, in agreement with an earlier report indicating that the R201C mutation leads to constitutive activation of Gsa protein (Landis et al., 1989) . We show that GNAS R201C alone was not sufficient to induce tumourigenesis by 12 months, but there was a two-fold increase in adenoma formation when Gpa33 tm1(GnasR201C)Wtsi/ þ mice were crossed with Apc Min/ þ mice. Furthermore, we have shown that constitutive activation of Gsa in intestinal cells results in increased activation of two of the most important signalling pathways in the development of colorectal cancers: the Wnt and ERK1/2 MAPK pathways.
Several reports have suggested that both the spatial and temporal production of cAMP are important in the promotion of intestinal tumourigenesis by COX-2 (reviewed by Taketo, 2006) . cAMP differentially regulates cell growth through the compartmental organization of cAMP signalling, which is predominantly the result of cell-type-specific isoform expression of phosphodiesterases, adenylate cyclases, protein kinase A (PKA) and cAMP effectors such as Rap-1 and B-raf (Houslay and Milligan, 1997; Stork and Schmitt, 2002; Conti and Beavo, 2007) . We found that the 1.5-fold increase in cAMP was accompanied by a 2.5-fold upregulation of the cAMP-specific phosphodiesterases Pde4a and Pde8b, but there was no change in the expression of Pde4b and Pde8a. As high levels of cAMP are subjected to negative feedback control by upregulation of phosphodiesterases (Conti and Beavo, 2007) , our data suggest that Gsa R201C is localized to the same cellular compartment(s) as Pde4a and Pde8b. In many cells cAMP serves to inhibit cell growth through inhibition of ERK1/2 MAPK; however, activation of ERK1/2 MAPK by cAMP has been shown to occur in a cell-type-specific manner through a number of mechanisms (Stork and Schmitt, 2002) . Briefly, cAMP has been shown to activate ERKs in a PKA-dependent manner: by stimulation of the PKA/Src/Rap-1/B-raf/MEK cascade, by stimulation of a PKA/Ras/B-raf or Raf-1/ MEK cascade, or through PKA-mediated inhibition of specific protein tyrosine phosphatases that inhibit ERKs. For Rap-1 to activate ERKs, the Raf isoform B-Raf must be expressed, as is the case in intestinal cells. cAMP has also been shown to activate ERKs independently of PKA, for example in the crypt-like intestinal cell-line T84 (Nishihara et al., 2004; Rudolph et al., 2004) , and this is thought to occur through activation of cAMP-GTPase exchange factors, which then directly activate the Rap-1/B-raf/MEK cascade. Furthermore, cAMP-mediated activation of ERK1/2 MAPK can stimulate proliferation and/or differentiation depending on the stimulus and cell type. In Gpa33 tm1(GnasR201C)Wtsi/ þ mice we saw both enhanced levels of activated phospho-ERK1/2 MAPK and increased levels of proliferation, as shown by an increased number of nuclei that stained positively for activated phospho-ERK1/2 MAPK and the proliferative marker Ki67 in the crypt region of the intestines. We found no changes in the markers for enteroendocrine, Paneth and goblet cells or apoptotic bodies, suggesting that cAMP may stimulate the proliferation of intestinal cell types in an ERK1/2 MAPK-dependent manner, but that it does not affect the differentiation or apoptosis of these cells. Although we have not established the exact mechanism of cAMPmediated activation of ERK1/2 MAPK following constitutive activation of Gsa in intestinal cells, activation of ERK1/2 MAPK is a significant contributory factor in the genesis of colorectal cancer. ERK1/2 MAPK activation is the result of activating mutations in either KRAS or BRAF in 40-50% of colorectal cancers (Bos, 1989; Brink et al., 2003) .
Expression of activated K-Ras from its endogenous locus or a transgene, and therefore activation of ERK1/2, by itself has been shown to be insufficient to induce neoplasia within the murine intestine (Sansom et al., 2006; Haigis et al., 2008; Luo et al., 2007 Luo et al., , 2009 ). However, in combination with inactivation of Apc, tumourigenesis is promoted (Sansom et al., 2006; Haigis et al., 2008; Luo et al., 2007 Luo et al., , 2009 ). In support, our data suggest that the intestinal expression of mutationally activated GNAS and the subsequent increase in activated ERK1/2 within the intestine were insufficient (by 12 months) to induce tumourigenesis alone, but that in combination with inactivation of Apc, the tumour number doubled.
Aberrant activation of the Wnt/b-catenin pathway is an initiating event in the vast majority of colorectal adenomas and cancers. The upregulation of c-Myc following activation of b-catenin is thought to be a critical mediator of the phenotypes of APC inactivation in the intestine (reviewed by Wilkins and Sansom, 2008) , which include cytoskeleton organization, apoptosis, cell cycle control and cell adhesion (Sieber et al., 2000) . Other models predict increased stem cell survival after loss of function of APC, which can be explained by enhanced expression of the Wnt target genes (Zhang et al., 2001) . Upregulation of the Wnt target genes Myc and Birc5 (survivin) in Gpa33 tm1(GnasR201C)Wtsi/ þ mice is likely to be because of the binding of constitutively activated Gsa to the regulator of G-protein signalling domain of Axin, thereby promoting the release of glycogen synthase kinase 3b from the APC/Axin complex and leading to reduced degradation of b-catenin (Castellone et al., 2005) . Our data suggest that a two fold upregulation of Myc and Birc5 is not sufficient to induce intestinal tumourigenesis in Gpa33 tm1(GnasR201C)Wtsi/ þ mice, by 12 months at least. However, clinical evidence from patients with McCune-Albright syndrome suggests that constitutive activation of Gsa is sufficient to induce intestinal tumour formation, although the APC status of these lesions is unknown (MacMahon, 1971; Weinstein et al., 1991) . APC and Gsa are both reported to bind to the regulator of G-protein signalling domain of axin and it is thought that APC hinders the activation of the Wnt pathway by Gsa. On the loss of APC, the threshold of Wnt pathway activation by constitutively active Gsa is thought to be lowered (Castellone et al., 2005) . In agreement, we found that the effects of loss of Apc and activation of Gnas were additive, as expression levels of the Wnt targets Myc and Birc5 were increased further in polyps from double-mutant mice when compared with those from Apc Min/ þ mice ( Supplementary Figure 2) . These findings may explain the increase in tumour formation, accompanied by no increase in tumour severity in Gpa33 tm1(GnasR201C)Wtsi/ þ Apc Min/ þ mice and why GNAS R201C and APC mutations have been found to co-occur in intestinal tumours (Sjoblom et al., 2006; Wood et al., 2007) .
Interestingly, cortisol-producing adrenocortical tumours have been associated with a number of syndromes other than McCune-Albright that feature the abnormalities of cAMP signalling. Examples are Cushing's syndrome due to mutations in GNAS, primary pigmented nodular adrenocortical disease (Carney Complex) due to mutations of the PKA regulatory subunit type 1A (PRKAR1A), macronodular adrenocortical disease associated with aberrant expression of G-protein-coupled receptors in the tumour tissue and, more recently, micronodular adrenocortical hyperplasia with inactivating mutations of phosphodiesterases PDE11A and PDE8B (Kirschner et al., 2000; Stratakis, 2003; Horvath et al., 2006 Horvath et al., , 2008 . Moreover, somatic activating mutations of the b-catenin gene (CTNNB1), which cause activation of the Wnt pathway, are the most frequent genetic defects in adrenocortical tumours and activating mutations of BRAF, KRAS, NRAS or EGFR, all of which result in activation of ERK1/2 MAPK, are also frequently found in this type of tumour (Kotoula et al., 2009) . Given the involvement of the phosphodiesterase Pde8b, Wnt and ERK1/2 MAPK pathways in intestinal tumourigenesis that is driven by activating mutations of Gsa in mice, it may be hypothesized that the above signalling molecules are localized to the same cAMP-signalling compartment in these two cell types and are involved in the development of both colorectal and adrenocortical cancers.
With the advancement of next-generation sequencing technology, genome-wide profiling of somatic mutations in human cancers is becoming a reality; therefore, a number of potentially interesting cancer genes are being identified. Data further suggests that only a few genes are commonly mutated 'mountains' and a much larger number of gene 'hills' are mutated at low frequency. Our data suggest that genes such as GNAS, which are mutated at a modest frequency in colorectal cancer, may also represent 'drivers' of tumourigenesis, making functional validation critical for establishing their diagnostic and therapeutic potential. Our data show that the R201C activating mutation of GNAS causes augmentation of both the Wnt and ERK1/2 MAPK pathways in the intestinal epithelium of mice and that the mutation co-operates with inactivation of Apc in intestinal tumour formation in vivo. Presumably, the activating R201H mutation of GNAS that has been identified in other human cancers contributes to tumour formation through the same mechanism. Taken together with previous human colorectal cancer mutational analysis (Sjoblom et al., 2006; Wood et al., 2007) , our data strongly suggest that activating mutations of GNAS are likely, together with inactivation of APC, to contribute to colorectal tumourigenesis.
Materials and methods
Generation of conditional Gpa33 tm1(GnasR201C)Wtsi/ þ mice The human full-length GNAS cDNA was synthesized to contain the codon change R201C. This cDNA was inserted into the pGpa33 LSL targeting vector (Figure 1 ; Orner et al., 2002) and targeted to the Gpa33 locus in C57BL/6J Bruce4 embryonic cells . Correctly targeted clones were identified by Southern blotting (probe primers: F: 5 0 -TGAGTTAGGGCTG CTTGCTT-3 0 and R: 5 0 -ATGGGTTCTGAGGATGATG C-3 0 ) on PstI digested genomic DNA.
Mice
Targeted embryonic cells were injected into albino C57BL/6J blastocysts and chimeras bred to C57BL/6J mice for germline transmission. All procedures were carried out in accordance with Home Office guidelines. Conditional Gpa33 tm1(GnasR201C)Wtsi/ þ and CMV-Cre À/À mice (Su et al., 2002) were crossed to produce Gpa33 tm1(GnasR201C)Wtsi/ þ and Gpa33 þ / þ littermates (heterozygous for CMV-Cre) for phenotyping. Gpa33 tm1(GnasR201C)Wtsi/ þ Cre þ /À mice were crossed with Apc Min/ þ mice to produce Gpa33 tm1(GnasR201C)Wtsi/ þ Apc Min/ þ mice and littermate controls. Mice were genotyped by polymerase chain reaction for the Gpa33 tm1(GnasR201C)Wtsi/ þ allele using the primers (1) 5 0 -CGAGG GAGGGCTAACTTTCT-3 0 ; (2) 5 0 -AAGAAGTGCTCCACC AATGC-3 0 and (3) 5 0 -CGTCCTGACCTCTGGAATCT-3 0 , which when multiplexed, detect the targeted and wild-type alleles of Gpa33. Expression of GNAS R201C was confirmed by RT-PCR using primers forward: 5 0 -ACATCACCGTGGC ACCCAGACCTCCCTC-3 0 and reverse: 5 0 -ATCTTTTTGTT GGCCTCACG-3 0 . Mice were genotyped by polymerase chain reaction for Apc Min using standard methods (Dietrich et al., 1993) . For assessment of adenoma formation the small and large (colon and rectum) intestines were collected. The small intestine was subdivided into three equal segments-denominated duodenum, jejunum and ileum. All were examined macroscopically for number, size and location of adenomas and embedded in paraffin wax.
Flow cytometric analysis of cAMP levels
The intestinal epithelial cells were scraped away from the muscular wall of the ileum (n ¼ 7, Gpa33 tm1(GnasR201C)Wtsi/ þ and n ¼ 5, Gpa33 þ / þ ) using a scalpel and sieved (70 mm) with ice-cold 4% formaldehyde in Ca 2 þ -and Mg 2 þ -free phosphate-buffered saline. The cells were fixed for 10 min, washed in phosphate-buffered saline, resuspended in phosphate-buffer saline containing 0.2% Tween-20 (Sigma, Gillingham, UK) for 10 min, washed again and resuspended in 1 ml 3% bovine serum albumin (Sigma: A3803). In all, 2 mg/ml anti-cAMP antibody (Abcam, Cambridge, MA, USA: ab24851) was added to the test samples and incubated for 3 h. The cells were washed and incubated in 3% bovine serum albumin containing 40 mg/ml fluorescein isothiocyanate-immunoglobulin G (Abcam: ab6785) for 1 h. The median fluorescence was determined by flow cytometry (FC-500, Beckman Coulter, High Wycombe, UK) and data were analysed using FlowJo Software (version7). Each test sample was normalized to the corresponding no primary antibody control and data were statistically analysed using two-tailed Student's t-test.
Immunohistochemistry and immunoblotting
Immunostaining was performed using the DAKO Autostainer Plus with the rabbit VECTASTAIN ELITE ABC horseradish peroxidase kit (Vector Laboratories, Burlingame, CA, USA). The primary antibodies used were anti-Ki67 (DCS-Innovative Diagnostik-Systeme, Hamburg, Germany), anti-chromogranin A (Abcam: ab15160) and anti-phospho-Thr202/Tyr204 p44/42 ERK1/2 MAPK (Cell Signalling Technology, Danvers, MA, USA: 20G11). Goblet cells were counted from Alcian blue-stained sections. Paneth cells, mitotic cells and apoptotic fragments were counted from haematoxylin and eosin stained sections. In all cases, a total of 30 crypts/villus were counted from the small intestine of six Gpa33 tm1(GnasR201C)Wtsi/ þ and six Gpa33 þ / þ mice and compared using the Mann-Whitney U test. Western blotting was performed using standard methods. Primary antibodies used were anti-p44/42 ERK1/2 MAPK (Cell Signalling Technology: 137F5) and anti-phospho-Thr202/Tyr204 p44/42 ERK1/2 MAPK. Band density was quantified using Image J software (NIH), normalized against b-actin and analysed using two-tailed Student's t-test.
Quantitative RT-PCR (qRT-PCR) Epithelial cells of the normal intestinal mucosa were scraped away from the muscular wall of the small intestine (n ¼ 11 of each genotype) using a scalpel. They were snap frozen in liquid nitrogen and total RNA was isolated using TRIzol (Invitrogen, Carlsbad, CA, USA). Polyps of 3 mm in diameter were dissected away from the muscular wall of the small intestine (n ¼ 6 of each genotype), snap frozen in liquid nitrogen and total RNA was isolated using the RNeasy Mini Kit (Qiagen, Crawley, UK). RNA was DNase treated using Turbo DNase (Ambion, Austin, TX, USA) and 1-2 mg total RNA was reverse transcribed using the BD Sprint kit with random hexamers (ABI, Foster City, CA, USA) according to the manufacturers' protocols. Quantitative PCRs were performed with SYBR Green (ABI) on the ABI 7900HT sequence detection system in accordance with the manufacturer's instructions, using cDNA obtained from 20 ng total RNA (see Supplementary Table 1 for primer sequences). The final quantitation was determined relative to the average C T of the house-keeping genes Gapdh and Actb (Livak and Schmittgen, 2001) . Data were statistically analysed using two-tailed Student's t-test.
